Abstract
Despite the recent advances in cancer handling, cytotoxic chemotherapy remains as the main approach for treating patients. These drugs are associated with a variety of acute and long-term side effects, including several levels of cardiac injury. Cardiotoxicity can be found in such patients as subclinical disease – where symptoms are not evidenced but changes can be observed in blood – or clinically symptomatic. The basis of chemotherapy-induced cardiotoxicity is multifactorial, but most of drugs present the same mechanism of damage: the generation of free radicals and redox homeostasis imbalance. In addition, several monoclonal antibodies employed in the personalized medicine against cancer have shown degrees of cardiotoxicity in patients. In this contect, this chapter discusses the main drugs capable to generate oxidative stress during cancer treatment, and highlight the main mechanisms mediated by redox mediators that are involved in cardiac damage.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205–219
Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647–656
Castaldo SA, Freitas JR, Conchinha NV, Madureira PA (2016) The tumorigenic roles of the cellular REDOX regulatory systems. Oxid Med Cell Longev:8413032
Okon IS, Zou M-H (2015) Mitochondrial ROS and cancer drug resistance: implications for therapy. Pharmacol Res 100:170–174
Kasapovic J, Pejic S, Todorovic A, Stojiljkovic V, Pajovic SB (2008) Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct 26:723–730
Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol 2012
Gutteridge JMC, Halliwell B (2018) Mini-review: oxidative stress, redox stress or redox success? Biochem Biophys Res Commun 502:183–186. Academic Press
Varrichi G, Ameri P, Cadeddu C et al (2018) Antineoplastic drug-induced cardiotoxicity: a redox perspective. Front Physiol 9:167
Min K, Kwon O-S, Smuder AJ, Wiggs MP, Sollanek KJ, Christou DD et al (2015) Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy. J Physiol 593:2017–2036
Albini A, Pennesi G, Donatelli F et al (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14–25
Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ (2004) Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30(2):181–191
Florescu M, Cinteza M, Vinereanu D (2013) Chemotherapy-induced cardiotoxicity. Maedica (Buchar) 8(1):59–67
Mihalcea DJ, Florescu M, Vinereanu D (2017) Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer. Am J Ther 24(1):e3–e11
Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12:931–947. Nature Publishing Group
Victorino VJ, Mencalha AL, Panis C (2015) Post-translational modifications disclose a dual role for redox stress in cardiovascular pathophysiology. Life Sci 129:42–47
Angsutararux P, Luanpitpong S, Issaragrisil S (2015) Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxid Med Cell Longev 2015:795602
Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y, Vergely C (2015) Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 36(6):326–348
WHO WHO. Cardiovascular Diseases [Internet]. (cited 2018, August 5). Available from: http://www.who.int/cardiovascular_diseases/en/
WHO WHO. Cancer [Internet]. (cited 2018, August 5]. Available from: http://www.who.int/cancer/en/
Yusuf SW, Razeghi P, Yeh ETH (2008) The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 33:163–196
Murphy KT (2016) The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am J Physiol – Hear Circ Physiol [Internet] 310:H466–H477. Available from: http://ajpheart.physiology.org/lookup/doi/10.1152/ajpheart.00720.2015
Wysong A, Couch M, Shadfar S, Li L, Rodriguez JE, Asher S et al (2011) NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol 178:1059–1068
Springer J, Tschirner A, Haghikia A, Von Haehling S, Lal H, Grzesiak A et al (2014) Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 35:932–941
Xu H, Crawford D, Hutchinson KR, Youtz DJ, Lucchesi PA, Velten M et al (2011) Myocardial dysfunction in an animal model of cancer cachexia. Life Sci 88:406–410
Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA (2010) Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol 37:347–353
Tian M, Asp ML, Nishijima Y, Belury MA (2011) Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol 39:1321–1326
Belloum Y, Rannou-Bekono F, Favier FB (2017) Cancer-induced cardiac cachexia: pathogenesis and impact of physical activity (Review). Oncol Rep 37:2543–2552
Egea J, Fabregat I, Frapart YM, Ghezzi P, Görlach A, Kietzmann T et al (2017) European contribution to the study of ROS: a summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol 13:94–162
Hinch ECA, Sullivan-Gunn MJ, Vaughan VC, McGlynn MA, Lewandowski PA (2013) Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice. J Cachexia Sarcopenia Muscle 4:287–293
Nathan C, Cunningham-Bussel A (2013) Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol 13:349–361
Mencalha A, Victorino VJ, Cecchini R, Panis C (2014) Mapping oxidative changes in breast cancer: understanding the basic to reach the clinics. Anticancer Res 34:1127–1140
Ayala A, Muñoz MF, Argüelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014
Marin-Corral J, Fontes CC, Pascual-Guardia S, Sanchez F, Olivan M, Argilés JM et al (2010) Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. Antioxid Redox Signal 12:365–380
Borges FH, Marinello PC, Cecchini AL, Blegniski FP, Guarnier FA, Cecchini R (2014) Oxidative and proteolytic profiles of the right and left heart in a model of cancer-induced cardiac cachexia. Pathophysiology 21:257–265
Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G et al (2015) Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 101:1874–1880
Singh-Manoux A, Shipley MJ, Bell JA, Canonico M, Elbaz A, Kivimaki M (2017) Association between inflammatory biomarkers and all-cause, cardiovascular and cancer-related mortality. CMAJ 189:E384–E390
Luan Y, Yao Y (2018) The clinical significance and potential role of c-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol 9:1–8
Panis C, Binato R, Correa S, Victorino VJ, Dias-Alves V, Herrera ACSA et al (2017) Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer. Cancer Chemother Pharmacol 80:469–478. Springer, Berlin/Heidelberg
Panis C, Victorino VJ, Herrera ACSA, Freitas LF, De Rossi T, Campos FC et al (2012) Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat 133:881–888
Amin KA, Mohamed BM, El-Wakil MAM, Ibrahem SO (2012) Impact of breast cancer and combination chemotherapy on oxidative stress, hepatic and cardiac markers. J Breast Cancer 15:306–312
Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R (2003) Health profiles in 5836 long-term cancer survivors. Int J Cancer 104:488–495
Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102:14–25
Zhu H, Sarkar S, Scott L, Danelisen I, Trush MA, Jia Z et al (2016) Doxorubicin redox biology: redox cycling, topoisomerase inhibition, and oxidative stress. React Oxyg Species (Apex) 1:189–198
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
Pilco-Ferreto N, Calaf GM (2016) Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol 49:753–762
Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905
Bahadır A, Kurucu N, Kadıoğlu M, Yenilmez E (2014) The role of nitric oxide in doxorubicin-induced cardiotoxicity: experimental study. Turkish J Hematol 31:68–74
Paulides M, Kremers A, Stohr W, Bielack S, Jurgens H, Treuner J et al (2009) Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 46:489–495
Zhou S, Palmeira CM, Wallace KB (2001) Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 121:151–157
Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AMM (2001) Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol 89:140–144
Guo RM, Xu WM, Lin JC, Mo LQ, Hua XX, Xi Chen P et al (2013) Activation of the p38 MAPK/NF-κB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Mol Med Rep 8:603–608
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717
Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153
Lipshultz SE, Alvarez JA, Scully RE (2008) Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525–533
Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL et al (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342–353
Myers CE (1988) Role of iron in anthracycline action. Organ Dir Toxicities Anticancer Drugs Dev Oncol:17–30
Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR (2007) Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50:1435–1441
Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879
Muggia FM (1997) Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 54:22–29
Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabrò R (2005) Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Pediatr Drugs 7:67–76
Wu AH (2008) Cardiotoxic drugs: clinical monitoring and decision making. Heart 94:1503–1509
Seifert CF, Nesser ME, Thompson DF (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28:1063–1072
Swain BSM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D et al (1997) Cardioprotection with dexrazoxane for doxorubicin- containing therapy in advanced breast cancer. J Clin Oncol 15:1318–1332
Manduteanu I, Dragomir E, Voinea M, Capraru M, Simionescu M (2007) Enoxaparin reduces H2O2-induced activation of human endothelial cells by a mechanism involving cell adhesion molecules and nuclear transcription factors. Pharmacology 79:154–162
Young E (2008) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122:743–752
Vejpongsa P, Yeh ETH (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64:938–945
Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M et al (1985) Doxorubicin-induced congestive heart failure in adults. Cancer 56:1361–1365
Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R et al (1989) Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118:92–98
Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M (2008) Biochemical markers for prediction of chemotherapy-induced cardiotoxicity systematic review of the literature and recommendations for use. Am J Clin Pathol 130:688–695
Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C et al (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109:3122–3131
Lipschultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB et al (1997) Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641–2648
Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A (2007) Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 43:1959–1966
Reichlin T, Reichlin T, Hochholzer W, Hochholzer W, Bassetti S, Bassetti S et al (2009) Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays. N Engl J Med 361:858–867
O’Brien PJ, Smith DEC, Knechtel TJ, MArchak MA, Pruimboom-Brees I, Brees DJ et al (2006) Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci 40:153–171
Dirican A, Levent F, Alacacioglu A, Kucukzeybek Y, Varol U, Kocabas U et al (2014) Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation to oxidative stress. Angiology 65:944–949
Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y et al (2015) Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 36:326–348
Hudis CA (2007) Trastuzumab — mechanism of action and use in clinical practice. N Engl J Med:39–51
Onitilo AA, Engel JM, Stankowski RV (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 5:154–166
Gemmete JJ, Mukherji SK (2011) Trastuzumab (Herceptin). AJNR Am J Neuroradiol 32:1373–1374
Bonci A, Lupica CR, Morales M (2015) Trastuzumab interruption and treatment-induced carciotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat 149:489–495
Dokmanovic M, Wu WJ (2015) Monitoring trastuzumab resistance and cardiotoxicity: a tale of personalized medicine. 1st ed. Adv Clin Chem
Ayres LR, de Almeida Campos MS, de Oliveira Gozzo T, Martinez EZ, Ungari AQ, de Andrade JM et al (2015) Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital. Int J Clin Pharm 37:365–372
Varga ZV, Ferdinandy P, Liaudet L, Pacher P (2015) Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol – Hear Circ Physiol 309:H1453–H1467
Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E (2018) Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev 2018:15
Sandoo A, Kitas GD, Carmichael AR (2015) Breast cancer therapy and cardiovascular risk: focus on trastuzumab. Vasc Health Risk Manag 11:223–228
Kabel AM, Elkhoely AA (2017) Targeting proinflammatory cytokines, oxidative stress, TGF-β1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomed Pharmacother 93:17–26
Leung HW, Chan AL (2015) Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data. Expert Opin Drug Saf 14:1661–1671
Ürün Y, Utkan G, Yalcin B, Akbulut H, Onur H, Oztuna DG et al (2015) The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer. Exp Oncol 37:53–57
Goyal V, Bews H, Cheung D, Premecz S, Mandal S, Shaikh B et al (2016) The cardioprotective role of N-acetyl cysteine amide in the prevention of doxorubicin and trastuzumab mediated cardiac dysfunction. Can J Cardiol
Lemos LGT, Victorino VJ, Herrera ACSA, Aranome AMF, Cecchini AL, Simão ANC et al (2015) Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer. Int Immunopharmacol 27:8–14
Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC et al (2015) Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 61:1164–1172
Moilanen T, Jokimäki A, Tenhunen O, Koivunen JP (2018) Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients. J Cancer Res Clin Oncol
Riccio G, Antonucci S, Coppola C, D’avino C, Piscopo G, Fiore D et al (2018) Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production. Front Physiol 9:38
Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L (2016) Melatonin as an antioxidant: under promises but over delivers. J Pineal Res 61:253–278
Ozturk M, Ozler M, Kurt YG, Ozturk B, Uysal B, Ersoz N et al (2011) Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity. J Pineal Res 50:89–96
Victorino VJ, Panis C, Campos FC, Cayres RC, Colado-Simao AN, Oliveira SR et al (2013) Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women. Age 35:1411–1421
Scripture CD, Figg WD, Sparreboom A (2005) Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 1:107–114
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265
Victorino VJ, Pizzatti L, Michelletti P, Panis C (2014) Oxidative stress, redox signaling and cancer chemoresistance: putting together the pieces of the puzzle. Curr Med Chem 21:3211–3226
Hadzic T, Aykin-Burns N, Zhu Y, Coleman MC, Leick K, Jacobson GM et al (2010) Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress. Free Radic Biol Med 48:1024–1033
Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67:3512–3517
Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65:8455–8460
Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL (2014) A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 15:47
Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T et al (2012) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133:89–97
Jezierska-Drutel A, Rosenzweig SA, Neumann CA (2013) Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res 119:107–125
Guigni BA, Callahan DM, Tourville TW, Miller MS, Fiske B, Voigt T et al (2018) Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am J Physiol Cell Physiol
Huang HL, Shi YP, He HJ, Wang YH, Chen T, Yang LW et al (2017) MiR-4673 modulates paclitaxel-induced oxidative stress and loss of mitochondrial membrane potential by targeting 8-oxoguanine-DNA glycosylase-1. Cell Physiol Biochem 42:889–900
Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, Sanchez-Rovira P, Ramirez-Tortosa MC (2010) New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem Toxicol 48:1425–1438
Goncalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R et al (2015) UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Ann Oncol 26:1692–1697
Kim R, Hahn S, Shin J, Ock CY, Kim M, Keam B et al (2016) The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis. Cancer Res Treat 48:907–916
Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H et al (2010) 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel) 2:1717–1730
Lestuzzi C, Tartuferi L, Corona G (2011) Capecitabine (and 5 fluorouracil) cardiotoxicity. Metabolic considerations. Breast J 17:564–567
Wyatt MD, Wilson 3rd DM. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009;66:788–799.
Lamberti M, Porto S, Zappavigna S, Addeo E, Marra M, Miraglia N et al (2014) A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicol Lett 227:151–156
Xiao H, Xiong L, Song X, Jin P, Chen L, Chen X et al (2017) Angelica sinensis polysaccharides ameliorate stress-induced premature senescence of hematopoietic cell via protecting bone marrow stromal cells from oxidative injuries caused by 5-fluorouracil. Int J Mol Sci 18
Hess JA, Khasawneh MK (2015) Cancer metabolism and oxidative stress: insights into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of methotrexate. BBA Clin 3:152–161
Sener MT, Sener E, Tok A, Polat B, Cinar I, Polat H et al (2012) Biochemical and histologic study of lethal cisplatin nephrotoxicity prevention by mirtazapine. Pharmacol Rep 64:594–602
Rtibi K, Selmi S, Grami D, Amri M, Sebai H, Marzouki L (2018) Contribution of oxidative stress in acute intestinal mucositis induced by 5 fluorouracil (5-FU) and its pro-drug capecitabine in rats. Toxicol Mech Methods 28:262–267
Bomfin LE, Braga CM, Oliveira TA, Martins CS, Foschetti DA, Santos AAQA et al (2017) 5-Fluorouracil induces inflammation and oxidative stress in the major salivary glands affecting salivary flow and saliva composition. Biochem Pharmacol 145:34–45
Afrin S, Giampieri F, Forbes-Hernandez TY, Gasparrini M, Amici A, Cianciosi D et al (2018) Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability. Free Radic Biol Med 126:41–54
Bywater MJ, Pearson RB, McArthur GA, Hannan RD (2013) Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer 13:299–314
Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421–433
Saleh EM (2015) Inhibition of topoisomerase IIalpha sensitizes FaDu cells to ionizing radiation by diminishing DNA repair. Tumour Biol 36:8985–8992
Kapiszewska M, Cierniak A, Elas M, Lankoff A (2007) Lifespan of etoposide-treated human neutrophils is affected by antioxidant ability of quercetin. Toxicol Vitr 21:1020–1030
Shin HJ, Kwon HK, Lee JH, Anwar MA, Choi S (2016) Etoposide induced cytotoxicity mediated by ROS and ERK in human kidney proximal tubule cells. Sci Rep 6:34064
Yadav N, Kumar S, Marlowe T, Chaudhary AK, Kumar R, Wang J et al (2015) Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents. Cell Death Dis 6:e1969
Haim N, Nemec J, Roman J, Sinha BK (1987) Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res 47:5835–5840
Kagan VE, Yalowich JC, Borisenko GG, Tyurina YY, Tyurin VA, Thampatty P et al (1999) Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol Pharmacol 56:494–506
Mahbub AA, Le Maitre CL, Haywood-Small SL, Cross NA, Jordan-Mahy N (2015) Glutathione is key to the synergistic enhancement of doxorubicin and etoposide by polyphenols in leukaemia cell lines. Cell Death Dis 6:e2028
Yadav N, Chandra D (2014) Mitochondrial and postmitochondrial survival signaling in cancer. Mitochondrion 16:18–25
Attia SM, Ahmad SF, Harisa GI, Mansour AM, El Sayed el SM, Bakheet SA (2013) Wogonin attenuates etoposide-induced oxidative DNA damage and apoptosis via suppression of oxidative DNA stress and modulation of OGG1 expression. Food Chem Toxicol 59:724–730
Kim DJ, Kim EJ, Lee TY, Won JN, Sung MH, Poo H (2013) Combination of poly-gamma-glutamate and cyclophosphamide enhanced antitumor efficacy against tumor growth and metastasis in a murine melanoma model. J Microbiol Biotechnol 23:1339–1346
Sekeroglu V, Aydin B, Sekeroglu ZA (2011) Viscum album L. extract and quercetin reduce cyclophosphamide-induced cardiotoxicity, urotoxicity and genotoxicity in mice. Asian Pac J Cancer Prev 12:2925–2931
Wang LF, Gong X, Le GW, Shi YH (2008) Dietary nucleotides protect thymocyte DNA from damage induced by cyclophosphamide in mice. J Anim Physiol Anim Nutr 92:211–218
Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81–128
Rezvanfar M, Sadrkhanlou R, Ahmadi A, Shojaei-Sadee H, Rezvanfar M, Mohammadirad A et al (2008) Protection of cyclophosphamide-induced toxicity in reproductive tract histology, sperm characteristics, and DNA damage by an herbal source; evidence for role of free-radical toxic stress. Hum Exp Toxicol 27:901–910
Shokrzadeh M, Ahmadi A, Naghshvar F, Chabra A, Jafarinejhad M (2014) Prophylactic efficacy of melatonin on cyclophosphamide-induced liver toxicity in mice. Biomed Res Int 2014:470425
Sengul E, Gelen V, Gedikli S, Ozkanlar S, Gur C, Celebi F et al (2017) The protective effect of quercetin on cyclophosphamide-Induced lung toxicity in rats. Biomed Pharmacother 92:303–307
Rehman MU, Tahir M, Ali F, Qamar W, Lateef A, Khan R et al (2012) Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid. Mol Cell Biochem 365:119–127
Korkmaz A, Topal T, Oter S (2007) Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 23:303–312
Chakraborty P, Roy SS, Basu A, Bhattacharya S (2016) Sensitization of cancer cells to cyclophosphamide therapy by an organoselenium compound through ROS-mediated apoptosis. Biomed Pharmacother 84:1992–1999
Chen XY, Xia HX, Guan HY, Li B, Zhang W (2016) Follicle loss and apoptosis in cyclophosphamide-treated mice: what’s the matter? Int J Mol Sci 17
Silva A, Girio A, Cebola I, Santos CI, Antunes F, Barata JT (2011) Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 25:960–967
Park KR, Nam D, Yun HM, Lee SG, Jang HJ, Sethi G et al (2011) beta-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. Cancer Lett 312:178–188
Jonas CR, Puckett AB, Jones DP, Griffith DP, Szeszycki EE, Bergman GF et al (2000) Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr 72:181–189
Patel JM, Block ER (1985) Cyclophosphamide-induced depression of the antioxidant defense mechanisms of the lung. Exp Lung Res 8:153–165
Roy SS, Chakraborty P, Biswas J, Bhattacharya S (2014) 2-[5-Selenocyanato-pentyl]-6-amino-benzo[de]isoquinoline-1,3-dione inhibits angiogenesis, induces p53 dependent mitochondrial apoptosis and enhances therapeutic efficacy of cyclophosphamide. Biochimie 105:137–148
Adams Jr. JD, Klaidman LK. Acrolein-induced oxygen radical formation. Free Radic Biol Med 1993;15:187–193.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Scandolara, T.B., Pires, B.R., Kern, R., Victorino, V.J., Panis, C. (2019). Oxidative Stress-Driven Cardiotoicity of Cancer Drugs. In: Chakraborti, S., Dhalla, N., Ganguly, N., Dikshit, M. (eds) Oxidative Stress in Heart Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-13-8273-4_3
Download citation
DOI: https://doi.org/10.1007/978-981-13-8273-4_3
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-8272-7
Online ISBN: 978-981-13-8273-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)